The company announced the resignation of board member John Brennan, who had served since 2021. His departure was not due to disagreements with the company's operations, policies, or practices. ImmunityBio is making considerable progress in discussions with the FDA, primarily revolving around its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC). The company is preparing to submit a supplemental Biologics License Application (sBLA) in 2025, which could potentially increase the number of patients benefiting from its therapy. BTIG has initiated coverage on ImmunityBio with a Buy rating, citing potential in the company's lead product, ANKTIVA, and its strategic partnership with the Serum Institute of India. ImmunityBio has also been assigned a unique permanent J-code for ANKTIVA by the Centers for Medicare & Medicaid Services, facilitating the billing process for the treatment.